semaglutide autoimmune GLP-1 Medications for Arthritis & Disease Semaglutide as a potential therapeutic

Sample sections were blocked in 5 % goat serum with 0.3 % Triton X-100 for 1 h at RT and then incubated overnight at 4 C with the following primary antibodies: mouse anti-GLP-1R (1:50, Santa Cruz, CA, USA), mouse anti-GLP-1(1:50, Santa Cruz, CA, USA), rabbit anti-Iba1 (1:500, Wako Chemicals, Tokyo, Japan), rabbit anti-GFAP (1:200, Cell Signalling, Boston, MA, USA), rabbit anti-NeuN (1:100, Proteintech, China), mouse anti-CGRP (1:100, Santa Cruz, CA, USA), and mouse anti-c-fos (1:100, Santa Cruz, CA, USA)

The drug bioconversion depends on their peculiar physicochemical properties and the interaction between the drug carrier and different sites (Liu et al., 2021)

For injectable GLP-1 therapies, this interaction is less of a concern since the medication enters the body directly through subcutaneous injection

Semaglutide is a type of drug known as a GLP-1 receptor agonist

Many patients experience 812 pounds of loss monthly on the microdose approach, achieving their goals in 69 months rather than rushing through higher doses

Alberti KGMM, Zimmet P, Shaw J